Amsoki-Cel Shows 66.7% Response in Advanced ICI-Resistant Melanoma
Pooled phase 1 and 1/2 trials found a 66.7% response rate in 15 patients at the recommended phase 2 dose of amsoki-cel, with no systemic IL-2 after infusion.
Topic
Topic
Pooled phase 1 and 1/2 trials found a 66.7% response rate in 15 patients at the recommended phase 2 dose of amsoki-cel, with no systemic IL-2 after infusion.